MedAI Verdict
All comparisons

eCART vs OpenEvidence

OpenEvidence costs a physician nothing. Access is free to NPI-verified clinicians and funded by advertising, which secondary sources say is mostly pharmaceutical. Its security page states HIPAA compliance, a standard BAA and SOC 2 Type II. Reddit users in September 2025 reported journal bias and a chest x-ray and pulmonary embolism error, and a medRxiv pilot that is not peer reviewed reported accuracy of 31% on a quick search and 39.5% in Deep Consult on subspecialty scenarios. A family physician reaches for it between patients. AgileMD's eCART answers a different need, ward deterioration alerts for a hospital response team, and at Yale the vendor reports a 13% relative mortality reduction since go-live, while a third-party blog argues the response team matters as much as the score.

Decision support · Reviewed November 2, 2026

eCART logo

eCART

by AgileMD

Early warning software that scores hospitalized ward patients for risk of deterioration from EHR data, for use by trained clinicians.

OpenEvidence logo

OpenEvidence

by OpenEvidence · founded 2022

Free physician-only literature-grounded Q&A, 1M consults/day.

When to pick each one

eCART

  • Deterioration alerts cleared in June 2024
  • Vendor-reported 13% mortality reduction at Yale
Read the full eCART review

OpenEvidence

  • Free for NPI-verified physicians, ad-funded
  • SOC 2 Type II and a standard BAA stated
  • Cited answers with NEJM and JAMA content
Read the full OpenEvidence review

Score

Each row shows points earned of points available under the published rubric.

eCART

56of 100

Solid choice

OpenEvidence

52of 100

Solid choice
Score by dimension for eCART and OpenEvidence
DimensioneCARTOpenEvidenceDifference
FDA clearance12 / 120 / 12+12
HIPAA / SOC2 / BAA10 / 100 / 10+10
EHR integrations (count)0 / 5.60 / 5.60
Top-3 EHR coverage (Epic / Oracle / Athena)0 / 4.80 / 4.80
Bidirectional write-back0 / 1.20 / 1.20
Peer-reviewed papers21 / 2121 / 210
RCT / meta-analysis / systematic review0 / 94.5 / 9-4.5
Funding & adoption signal3 / 1212 / 12-9
Pricing transparency1.3 / 2.52.5 / 2.5-1.2
Years in market0 / 64.2 / 6-4.2

Scroll horizontally to see every column.

How scores are computed

Pricing

eCART

TierMonthlyAnnualNotes
Enterprisen/an/aNo public price. There is no pricing page; the site offers a demo request only.

OpenEvidence

TierMonthlyAnnualNotes
Plann/an/aFree for NPI-verified physicians (ad-funded).

Compliance and integrations

Documented from each vendor’s own pages.

SpeceCARTOpenEvidence
Free tierNo / unverifiedYes
HIPAAYesNo / unverified
SOC 2 Type IIYesNo / unverified
EHR integrationsNot specifiedNot specified
Foundedn/a2022
HQUSUS

Scroll horizontally to see both columns.

Common questions

Open the full decision support comparison

Differential diagnosis, treatment guidance, drug interactions, evidence-grounded Q&A. The CDS landscape ranges from the UpToDate gold standard to physician-only OpenEvidence. We compared what clinicians actually use.